Insulin as initial therapy for type 2 diabetes is not in the patient's best interest

Endocrine Practice

Volumn 10, Issue 3, 2004, Pages 208-212

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN;

CARDIOVASCULAR DISEASE; DRUG COMBINATION; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; THIAZOLIDINEDIONES;

EID: 11844283483     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.3.208     Document Type: Note

References (34)

1. Bell DSH, Mayo MS. Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus. Endocr Pract. 1997;3:73-76.
2. Bell DSH, Mayo MS. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin Endocr Pract. 1998;4:82-85.
3. Bell DSH, Mayo MS. Weight loss in patients with diabetes treated with a metformin-sulfonylurea combination in comparison with twice-daily mixed insulin. Endocr Pract. 1998;4:360-364.
4. Bell DSH, Ovalle F. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea? Endocr Pract. 2000;6:293-295.
5. Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998;4:l46-147.
6. Bell DSH, Ovalle F, Shadmany S. Conversion from troglitazone to rosiglitazone [letter]. Endocr Pract. 2001; 7:326.
7. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275.
8. Bell DSH, Ovalle F. Five-year follow-up of triple oral therapy for type 2 diabetes mellitus. Paper presented at: 85th Annual Meeting of the Endocrine Society; June 2003; Philadelphia, PA.
9. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract. 2001;7:135-138.
10. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
11. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on pancreatic beta cell function of subjects with type 2 diabetes mellitus. Diabetes. 2003;52(Suppl 1).
12. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
14. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000;93:369-374.
15. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A. 1997;94:4637-4641.
16. Hull RL, Andrikopoulos S, Verchere CB, et al. Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes. 2003;52:372-379.
17. Zhenping S, Hall R, Kodama K, et al. Long-term rosiglitazone and metformin treatment reduces the severity of islet amyloid but does not prevent its formation. Diabetes. 2003;52:1464.
18. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte beta-cell relationships. Proc Natl Acad Sci U S A. 1994;91:10878-10882.
19. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26:1589-1596.
20. Gremlich S, Bonny C, Waeber G, Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem. 1997;272:30261-30269.
21. Cnop M, Grupping A, Hoorens A, Bouwens L, Pipeleers-Marichal M, Pipeleers D. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol. 2000;156:237-244.
22. Butler AE, Janson J, Boner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52: 102-110.
23. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273:3547-3550.
24. Lister CA, Boam D, Bretherton-Watt D, et al. Rosiglitazone increases pancreatic islet area, number and insulin content but not insulin gene expression. Diabetologia. 1998;41(Suppl 1):A69.
25. Porter LE, Freed MI, Jones NP, Biswas N. Rosiglitazone improves beta cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes. Diabetes. 2000;49(Suppl 1):A122.
26. Clauson P, Linnarsson R, Gottsater A, Sundkvist G, Grill V. Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med. 1994;11:794-801.
27. Stratton IM, Adler AJ, Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
28. Khaw KT, Wareham N, Luben R, et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
29. Haffner SM, Greenberg AS, Weston WM, Chen H, William K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
30. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract. 2002;8: 406-410.
31. Freed MI, Ratner R, Mattovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
32. Winkler K, Konrad T, Fullert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003;26:2588-2594.
33. Yue TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2001;104:2588-2594.
34. Sauer WH, Berlin JA, Kimmel SF. Thiazolidinediones and prevention of myocardial infarction in patients with type 2 diabetes. Circulation. 2002;106(Suppl 1):562.